Literature DB >> 9665484

Immunohistochemical localization of somatostatin receptors sst2A in human tumors.

J C Reubi1, A Kappeler, B Waser, J Laissue, R W Hipkin, A Schonbrunn.   

Abstract

Human tumors frequently express somatostatin receptors. However, none of the receptor subtype proteins have been individually visualized in normal or neoplastic human tissues. Here, the distribution of the sst2A receptor was investigated using immunohistochemistry with the specific anti-peptide antibody R2-88 in 47 human tumors. All tumors selected for their abundance of sst2 mRNA and/or strong binding of the sst2-preferring ligand 125I-labeled Tyr3-octreotide were specifically immunostained with R2-88. Conversely, all tumors without somatostatin binding or expressing predominantly other somatostatin receptor subtype mRNAs (sst1 or sst3) were not specifically immunostained by R2-88. Specificity was shown in immunoblots, demonstrating receptor migration as a 70-kd broad band. In immunohistochemical and immunoblotting experiments, the abolition of staining after antibody blockade with antigen peptide was demonstrated. Immunostaining was identified in cryostat and in formalin-fixed, paraffin-embedded sections. Heat-induced epitope retrieval was necessary to visualize sst2A receptors in formalin-fixed sections. Moreover, because of occasional high nonspecific staining, the demonstration of complete abolition of immunostaining by treatment with antigen peptide was a prerequisite for the correct identification of sst2A-positive tumors. The sst2A receptors were clearly located at the membrane of the tumor cells. These results provide the first localization of a somatostatin receptor subtype in human tissues at the cellular level. The sst2A receptor identification and visualization in tumors with simple immunohistochemical methods in formalin-fixed, paraffin-embedded material will open new diagnostic opportunities for pathologists.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665484      PMCID: PMC1852945          DOI: 10.1016/S0002-9440(10)65564-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients.

Authors:  E T Janson; A Gobl; K M Kälkner; K Oberg
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

2.  Coupling specificity between somatostatin receptor sst2A and G proteins: isolation of the receptor-G protein complex with a receptor antibody.

Authors:  Y Z Gu; A Schonbrunn
Journal:  Mol Endocrinol       Date:  1997-05

Review 3.  Molecular pharmacology of somatostatin-receptor subtypes.

Authors:  C Bruns; G Weckbecker; F Raulf; K Kaupmann; P Schoeffter; D Hoyer; H Lübbert
Journal:  Ann N Y Acad Sci       Date:  1994-09-15       Impact factor: 5.691

4.  Somatostatin-receptor imaging in the localization of endocrine tumors.

Authors:  S W Lamberts; W H Bakker; J C Reubi; E P Krenning
Journal:  N Engl J Med       Date:  1990-11-01       Impact factor: 91.245

5.  High incidence of somatostatin receptors in human meningiomas: biochemical characterization.

Authors:  J C Reubi; R Maurer; J G Klijn; S Z Stefanko; J A Foekens; G Blaauw; M A Blankenstein; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  1986-08       Impact factor: 5.958

6.  The two isoforms of the mouse somatostatin receptor (mSSTR2A and mSSTR2B) differ in coupling efficiency to adenylate cyclase and in agonist-induced receptor desensitization.

Authors:  M Vanetti; G Vogt; V Höllt
Journal:  FEBS Lett       Date:  1993-10-04       Impact factor: 4.124

7.  Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors.

Authors:  Y Greenman; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1994-02       Impact factor: 5.958

8.  In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue.

Authors:  J C Reubi; B Waser; U Horisberger; E Krenning; S W Lamberts; J O Gebbers; P Gersbach; J A Laissue
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

9.  Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains.

Authors:  J C Adams
Journal:  J Histochem Cytochem       Date:  1992-10       Impact factor: 2.479

10.  Relevance of Somatostatin Receptors and Other Peptide Receptors in Pathology.

Authors:  Jean Claude Reubi
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

View more
  30 in total

Review 1.  Classic and recent special stains used in differential diagnosis of endocrine tumors.

Authors:  G Bussolati; M Volante; M Papotti
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

2.  Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients.

Authors:  Beatrice Waser; Renzo Cescato; Qisheng Liu; Yachu J Kao; Meike Körner; Emanuel Christ; Agnes Schonbrunn; Jean Claude Reubi
Journal:  Am J Pathol       Date:  2012-05       Impact factor: 4.307

3.  Clinicopathological value of somatostatin type 2A and estrogen receptor immunoreactivity in human breast carcinoma.

Authors:  M Pilichowska; N Kimura; A Suzuki; R Yoshida; M Schindler; H Nagura
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

4.  Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.

Authors:  N Benali; P Cordelier; D Calise; P Pages; P Rochaix; A Nagy; J P Esteve; P M Pour; A V Schally; N Vaysse; C Susini; L Buscail
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

5.  Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy.

Authors:  D Ferone; R Pivonello; D J Kwekkeboom; F Gatto; P Ameri; A Colao; R R de Krijger; F Minuto; S W J Lamberts; P M van Hagen; L J Hofland
Journal:  J Endocrinol Invest       Date:  2011-07-13       Impact factor: 4.256

6.  Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas.

Authors:  E Thodou; G Kontogeorgos; D Theodossiou; M Pateraki
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

Review 7.  Pancreatic cancer - a continuing challenge in oncology.

Authors:  Attila Zalatnai
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

8.  Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.

Authors:  Eva Ludvigsen; Mats Stridsberg; John E Taylor; Michael D Culler; Kjell Oberg; Eva T Janson
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

Review 9.  Medical treatment for gastro-entero-pancreatic neuroendocrine tumours.

Authors:  Rossana Berardi; Francesca Morgese; Mariangela Torniai; Agnese Savini; Stefano Partelli; Silvia Rinaldi; Miriam Caramanti; Consuelo Ferrini; Massimo Falconi; Stefano Cascinu
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

10.  Expression of the SST receptor 2 in uveal melanoma is not a prognostic marker.

Authors:  Mariam Kouch-el Filali; Emine Kilic; Marleen Melis; Annelies de Klein; Marion de Jong; Gregorius P M Luyten
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-06       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.